Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center
- PMID: 15654688
- DOI: 10.1002/hed.20127
Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center
Abstract
Background: Olfactory neuroblastoma (ONB) is a rare tumor arising from the olfactory neuroepithelium. There is no universally accepted staging system, and treatment approaches lack uniformity. We present one institution's experience with this tumor and the results of therapy.
Methods: Thirty patients treated for ONB at The University of Texas M. D. Anderson Cancer Center between 1979 and 2002 were retrospectively reviewed. The diagnosis of ONB was histologically confirmed for each patient.
Results: The mean follow-up was 7.32 years. In 77% of cases, patients received treatment with surgery followed by postoperative radiation therapy. Sixteen percent received chemotherapy as part of their initial treatment. Overall 5-year and 10-year survival rates were 89% and 81%, respectively. Nine patients whose disease was initially stage C had a recurrence. The mean time for recurrence was 4.67 years.
Conclusions: The M. D. Anderson Cancer Center approach to ONB is complete surgical resection, usually involving a craniofacial approach, with postoperative radiation therapy. This approach seems to be curative in early-stage disease. Late recurrence warrants long-term follow-up.
2004 Wiley Periodicals, Inc.
Similar articles
-
Esthesioneuroblastoma: the Northwestern University experience.Laryngoscope. 2003 Jan;113(1):155-60. doi: 10.1097/00005537-200301000-00029. Laryngoscope. 2003. PMID: 12514401
-
Therapy and prognosis of intracranial invasive olfactory neuroblastoma.Otolaryngol Head Neck Surg. 2011 Dec;145(6):951-5. doi: 10.1177/0194599811416752. Epub 2011 Aug 8. Otolaryngol Head Neck Surg. 2011. PMID: 21825099
-
Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):992-7. doi: 10.1016/j.ijrobp.2009.09.019. Epub 2010 Mar 16. Int J Radiat Oncol Biol Phys. 2010. PMID: 20231062
-
Endoscopic resection of esthesioneuroblastoma.Am J Rhinol. 2001 Jul-Aug;15(4):271-9. Am J Rhinol. 2001. PMID: 11554661 Review.
-
Olfactory neuroblastoma: a case report and review of the literature.Ear Nose Throat J. 2005 Mar;84(3):150-2. Ear Nose Throat J. 2005. PMID: 15871582 Review.
Cited by
-
Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.Radiat Oncol. 2015 Apr 15;10:88. doi: 10.1186/s13014-015-0397-5. Radiat Oncol. 2015. PMID: 25888953 Free PMC article.
-
Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab.Rare Tumors. 2012 Apr 12;4(2):e33. doi: 10.4081/rt.2012.e33. Epub 2012 Jun 12. Rare Tumors. 2012. PMID: 22826790 Free PMC article.
-
Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database.Head Neck. 2017 Oct;39(10):1962-1968. doi: 10.1002/hed.24770. Epub 2017 Aug 17. Head Neck. 2017. PMID: 28815831 Free PMC article.
-
Survival and failure outcomes in locally advanced esthesioneuroblastoma: a single centre experience of 15 patients.Eur Arch Otorhinolaryngol. 2013 May;270(6):1897-901. doi: 10.1007/s00405-012-2280-4. Epub 2012 Nov 21. Eur Arch Otorhinolaryngol. 2013. PMID: 23179939
-
Treatment Strategies and Outcomes of Pediatric Esthesioneuroblastoma: A Systematic Review.Front Oncol. 2020 Jul 24;10:1247. doi: 10.3389/fonc.2020.01247. eCollection 2020. Front Oncol. 2020. PMID: 32793498 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical